Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 6/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | HTR5A | P47898 | 2/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | CDK4 | P11802 | 2/20 | 0.33 |
| ▸ | CCND1 | P24385 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MPL | P40238 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18156839 | 0.89 | TDO2 (0.36) | TDO2HTR2BHTR5ABCHEPARP14 | |
| SCHEMBL18156837 | 0.82 | CDK4 (0.33) | PARP14CDK4CCND1 | |
| SCHEMBL22357259 | 0.82 | TDO2 (0.36) | TDO2HTR2BHTR5ABCHEPARP14 | |
| SCHEMBL21393974 | 0.81 | MEN1 (0.37) | MEN1KMT2A | |
| SCHEMBL22058517 | 0.81 | ADORA3 (0.37) | MEN1KMT2A | |
| SCHEMBL21394267 | 0.81 | MEN1 (0.37) | MEN1KMT2A | |
| SCHEMBL21393976 | 0.81 | ADORA3 (0.37) | MEN1KMT2A | |
| SCHEMBL21393977 | 0.81 | MEN1 (0.37) | MEN1KMT2A | |
| SCHEMBL12097032 | 0.81 | TDO2 (0.38) | TDO2HTR2BHTR5ABCHEPARP14 | |
| SCHEMBL15593044 | 0.81 | ADORA2A (0.39) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230126850-A1 | HETEROCYCLIC SPIRO COMPOUNDS | MERCK PATENT GMBH (DE) | 2023-04-27 | — | — | US | disclosed |
| US-20230126850-A1 | HETEROCYCLIC SPIRO COMPOUNDS | MERCK PATENT GMBH (DE) | 2023-04-27 | — | — | US | disclosed |
| US-11545634-B2 | Heterocyclic spiro compounds | MERCK PATENT GMBH (DE) | 2023-01-03 | — | — | US | disclosed |
| US-10777750-B2 | Heterocyclic spiro compounds | BASF SE (DE) | 2020-09-15 | — | — | US | disclosed |
| US-20200266364-A1 | HETEROCYCLIC SPIRO COMPOUNDS | MERCK PATENT GMBH (DE) | 2020-08-20 | — | — | US | disclosed |
| US-20160308147-A1 | HETEROCYCLIC SPIRO COMPOUNDS | MERCK PATENT GMBH (DE) | 2016-10-20 | — | — | US | disclosed |
| US-20160308147-A1 | HETEROCYCLIC SPIRO COMPOUNDS | MERCK PATENT GMBH (DE) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160308147-A1 | HETEROCYCLIC SPIRO COMPOUNDS | NES, KCNC1, HCN4 | TDO2 3696/4885HTR2B 2447/4885HTR5A 2974/4885 |
| US-11545634-B2 | Heterocyclic spiro compounds | NES, KCNC1, HCN4 | TDO2 3696/4885HTR2B 2447/4885HTR5A 2974/4885 |
| US-20200266364-A1 | HETEROCYCLIC SPIRO COMPOUNDS | NES, KCNC1, HCN4 | TDO2 3696/4885HTR2B 2447/4885HTR5A 2974/4885 |
| US-20230126850-A1 | HETEROCYCLIC SPIRO COMPOUNDS | NES, KCNC1, HCN4 | TDO2 3696/4885HTR2B 2447/4885HTR5A 2974/4885 |
| US-10777750-B2 | Heterocyclic spiro compounds | NES, KCNC1, HCN4 | TDO2 3696/4885HTR2B 2447/4885HTR5A 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.